Relationship of Oxidant and Antioxidant Markers to Asthma Severity in Egyptian Asthmatic Children
DOI:
https://doi.org/10.3889/oamjms.2017.149Keywords:
asthmatic children, asthma severity, antioxidant markers, an oxidant, RelationshipAbstract
BACKGROUND: Asthma is a chronic airway disease which is characterized by oxidant antioxidant imbalance with the generation of oxidative stress related mediators.
AIM: The study aimed to evaluate the role of asymmetric dimethylarginine, and malondialdehyde as oxidant markers and serum paraoxonase activity as an antioxidant marker in asthma, and to determine their relationship to the asthma severity and lung function among asthmatic children in Egypt.
PATIENTS AND METHODS: This case control study was conducted on sixty patients with asthma compared with sixty apparently healthy children of matched age and sex.
RESULTS: Serum concentrations of oxidant markers as asymmetric dimethylarginine and malondialdehyde were significantly increased in asthmatic patients while anti-oxidant marker as paraoxonase activity was significantly decreased compared to healthy controls (P < 0.05). ANOVA test revealed highly significant elevation of the serum concentrations of oxidant markers while anti-oxidant marker was significantly decreased in severe asthmatic patients (P < 0.001) compared to the patients with moderate and mild asthma respectively. Serum malondialdehyde concentration was a strong predictor of asthma severity by multiple regression analysis (P < 0.05).
CONCLUSION: The study revealed an imbalance between oxidative and antioxidant defence systems in asthmatic children. Serum concentration of malondialdehyde was the most predictive biomarker having a significant association with asthma severity.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Courtney AU, McCarter DF, Pollart SM. Childhood Asthma: Treatment Update. Am Fam Physician. 2010; 71(10): 1959-68.
Janahi IA, Bener A, Bush A. Prevalence of asthma among schoolchildren: International Study of Asthma and Allergies in Childhood, Qatar. Pediatr Pulmonol. 2006;41:80–86. https://doi.org/10.1002/ppul.20331 PMid:16283628
Masoli M, Fabian D, Holt S, Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004; 59: 469–478. https://doi.org/10.1111/j.1398-9995.2004.00526.x PMid:15080825
Dut R, Dizdar EA, Birben E, Sackesen C, Soyer OU, Besler T. Oxidative stress and its determinants in the airways of children with asthma. Allergy. 2008; 63: 1605-9. https://doi.org/10.1111/j.1398-9995.2008.01766.x PMid:19032232
Bowler RP. Oxidative stress in the pathogenesis of asthma. Curr Allergy Asthma Rep. 2004; 4: 116–22. https://doi.org/10.1007/s11882-004-0056-7 PMid:14769260
Psarras S, Caramori G, Contoli M, Papadopoulos N, Papi A. Oxidants in asthma and in chronic obstructive pulmonary disease. Curr Pharm Des. 2005; 11: 2053–62. https://doi.org/10.2174/1381612054065774 PMid:15974958
Grasemann H, Al-Saleh S, Scott JA. Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with cystic fibrosis. Am J Respir Crit Care Med. 2011; 183(10):1363-8. https://doi.org/10.1164/rccm.201012-1995OC PMid:21278301
Bulau P, Zakrzewicz D, Kitowska K. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. Am J Physiol Lung Cell Mol Physiol. 2007; 292(1):L18-24. https://doi.org/10.1152/ajplung.00076.2006 PMid:16891395
Klein E, Weigel J, Buford MC, Holian A, Wells SM. Asymmetric dimethylarginine potentiates lung inflammation in a mouse model of allergic asthma. Am J Physiol Lung Cell Mol Physiol. 2010; 299(6): L816-25. https://doi.org/10.1152/ajplung.00188.2010 PMid:20889675 PMCid:PMC3006265
Wells SM, Buford MC, Migliaccio CT, Holian A. Elevated asymmetric dimethylarginine alters lung function and induces collagen deposition in mice. Am J Respir Cell Mol Biol. 2009; 40(2):179-88. https://doi.org/10.1165/rcmb.2008-0148OC PMid:18703795 PMCid:PMC2633140
Holguin F, Comhair SA, Hazen SL. An association between L-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype. Am J Respir Crit Care Med. 2013; 187: 153–159. https://doi.org/10.1164/rccm.201207-1270OC PMid:23204252 PMCid:PMC3570651
Gennaro CV, Bianchi M, Pascale V. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med Sci Monit. 2009; 15(4): 91–101.
Gruber HJ, Mayer C, Meinitzer A. Asymmetric dimethylarginine (ADMA) is tightly correlated with growth in juveniles without correlations to obesity related disorders. Exp Clin Endocrinol Diabetes. 2008; 116: 520–24. https://doi.org/10.1055/s-2008-1062712 PMid:18523919
Bowler RP, Crapo JD. Oxidative stress in airways: is there a role for extracellular superoxide dismutase? Am J Respir Crit Care Med. 2002; 166: S38-43. https://doi.org/10.1164/rccm.2206014 PMid:12471087
Iribarren C, Tolstykh IV, Eisner MD. Are patients with asthma at increased risk of coronary heart disease? Int J Epidemiol 2004; 33: 743-8. https://doi.org/10.1093/ije/dyh081 PMid:15131088
Lohman TG, Roche AF, Martorell R. Anthropometric standardization reference manual. Champaign, IL: Human kinetics Publishers, 1988. PMCid:PMC279682
Tanner JM, Miernaux J, Jarman S. Growth and physique studies, in Human Biology: A Guide to Field Methods, J. S. Weiner and J. A. Lourie, Eds., pp. 315–340, Blackwell Publications, Oxford, UK, 1969.
WHO AnthroPlus for personal computers, Manual Software for assessing growth of the world's children and adolescents, 2011. Geneva. (http://www.who.int/growthref/ tools /en/).
Global Initiative for Asthma [GINA]. GINA report, global strategy for asthma management and prevention, 2016.
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005; 26:319-338. https://doi.org/10.1183/09031936.05.00034805 PMid:16055882
Dreborg S, Frew A. Allergen standardization and skin tests. Allergy. 1993; 48: 49-82. https://doi.org/10.1111/j.1398-9995.1993.tb04756.x
Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, et al. Determination of asymmetric dimethylarginine using a novel ELISA assay. Clin Chem Lab Med. 2004; 42(12):1377-83. https://doi.org/10.1515/CCLM.2004.257 PMid:15576299
Hunter MIS, Nlemadim BC, Davidson DL. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem Res. 1985; 10: 1645-52. https://doi.org/10.1007/BF00988606 PMid:4088434
Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities. Drug Metab Disp. 1991; 19: 100–106. PMid:1673382
Vercelli D. Molecular regulation of the IgE immune response. Clin Exp Allergy. 1995; 25:S2:43-5. https://doi.org/10.1111/j.1365-2222.1995.tb00420.x PMid:8590342
Koterba AP, Saltoun CA: Allergy Asthma Proc. Asthma classification. 2012; 33(Suppl 1):S28-31.
Elnady GH, Fouda EM, Elsheikh OM, ElAlameey IR, Elshafie AI, Sherif L S., et al: Serum vitamin D level as a predictor of bronchial asthma in Egyptian Children. Journal of the Arab Society for Medical Research. 2013; 8:67–73. https://doi.org/10.4103/1687-4293.123788
Lau EMT, Morgan PE, Belousova EG. Asymmetric dimethylarginine and asthma: results from the Childhood Asthma Prevention Study. Eur Respir J. 2013; 41: 1234–1237. https://doi.org/10.1183/09031936.00162212 PMid:23633615
Scott JA, North ML, Rafii M. Asymmetric dimethylarginine is increased in asthma. Am J Respir Crit Care Med. 2011; 184: 779–785. https://doi.org/10.1164/rccm.201011-1810OC PMid:21719758
Lara A, Khatri SB, Wang Z. Alterations of the arginine metabolome in asthma. Am J Respir Crit Care Med. 2008; 178: 673–681. https://doi.org/10.1164/rccm.200710-1542OC PMid:18635886 PMCid:PMC2556449
Carraro S, Giordano G, Piacentini G. Asymmetric dimethylarginine in exhaled breath condensate and serum of children with asthma. Chest. 2013; 144: 405–410. https://doi.org/10.1378/chest.12-2379 PMid:23412513
Narula MK, Ahuja GK, Whig J, Narang AP, Soni RK. Status of lipid peroxidation and plasma iron level in bronchial asthmatic patients. Indian J Physiol Pharmacol. 2007; 51: 289-92. PMid:18341227
Cakmak A, Zeyrek D, Atas A, Selek S, Erel O. Oxidative status and paraoxonase activity in children with asthma. Clin Invest Med. 2009; 32(5): 327-34. https://doi.org/10.25011/cim.v32i5.6920
Can M, Mungan AG, Acıkgoz F, Yuksel B, Demirtas S, Tomac N. Effect of Montelukast Treatment on Serum Paraoxonase Activity in Asthmatic Children. Turk J Med Sci. 2007; 37 (6): 373-6.
Górnicka G, Bełtowski J, Wójcicka G, Jamroz A. Serum paraoxonase activity, total antioxidant potential and lipid peroxidation products in children with bronchial asthma exacerbation. Wiad Lek. 2002; 55:257-63. PMid:12235690
Ekmekci OB, Donma O, Ekmekci H. Plasma paraoxonase activities, lipoprotein oxidation, and trace element interaction in asthmatic patients. Biol Trace Elem Res. 2006; 111: 41-52. https://doi.org/10.1385/BTER:111:1:41
Kabaroglu C, Mutaf I, Boydak B. Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes. Acta Cardiol. 2004; 59:606-11. https://doi.org/10.2143/AC.59.6.2005242 PMid:15636443
Schanen JG, Iribarren C, Shahar E. Asthma and incident cardiovascular disease: the Atherosclerosis Risk in Communities Study. Thorax. 2005; 60: 633-8. https://doi.org/10.1136/thx.2004.026484 PMid:16061703 PMCid:PMC1747501
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
